Inexios Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-12-2024
- Paid Up Capital ₹ 1.00 M
as on 09-12-2024
- Company Age 18 Year, 28 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 10.71%
(FY 2023)
- Profit 14.29%
(FY 2023)
- Ebitda -4.70%
(FY 2023)
- Net Worth 1.66%
(FY 2023)
- Total Assets 1.78%
(FY 2023)
About Inexios Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Srivathsa, Nandan Sastry, and Sriram Chakravarti serve as directors at the Company.
- CIN/LLPIN
U24232KA2006PTC041018
- Company No.
041018
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2006
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Inexios Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Srivathsa  | Director | 16-Apr-2018 | Current |
Nandan Sastry  | Director | 16-Mar-2015 | Current |
| Sriram Chakravarti | Director | 20-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Inexios Pharmaceuticals.
Inexios Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.71% increase. The company also saw a substantial improvement in profitability, with a 14.29% increase in profit. The company's net worth moved up by a moderate rise of 1.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Inexios Pharmaceuticals?
Unlock access to Inexios Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Nadathur Estates Private LimitedActive 24 years 10 monthsRajesh Srivathsa, Nandan Sastry and 1 more are mutual person
- Kafnu Otis Bali Private LimitedActive 14 years 3 months
Rajesh Srivathsa, Nandan Sastry and 1 more are mutual person
- Tree Hill Estates Private LimitedActive 18 years 2 months
Rajesh Srivathsa, Nandan Sastry and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Inexios Pharmaceuticals?
Inexios Pharmaceuticals has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Inexios Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Inexios Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
